Technical Stepan Information

Stepan Company 22 Frontage Road Northfield, Illinois 60093 Telephone (847) 446-7500

www.stepan.com

MAMMALIAN TOXICOLOGY OF ALKYL DIMETHYL BENZYL/ETHYL BENZYL AMMONIUM CHLORIDES Applicable to these current Stepan products:

BTC® 2125 M-80% BTC® 2125M	BTC® 2125 M P40 AGENT 2248-14	SO/SAN® 30M			
Applicable to these inactive Stepan products:					

BTC® 2125 BTC® 2125-80%	BTC® 2125 P40

Toxicological Information:

Test/Conditions	Results/Classification	<u>References</u>
Acute Oral Toxicity (rat)(14 day) n=5/sex/dose	LD ₅₀ (Lethal Dose) is between 50 and 500 mg/kg (moderately to slightly toxic orally at 50% active)	Stepan Study No. 87-005E
Acute Dermal Toxicity (rabbit) (14 day) n=5/sex/dose	LD ₅₀ is found to be greater than 2000M mg/kg (slightly toxic dermally)	Stepan Study No. 87-005F
Primary Eye Irritation (rabbit) (21 day) n=6	29.9/110.0 @1% active (moderately irritating)	Stepan Study No. 05-002C
Repeated Eye Instillation (rabbit)(3 weeks) n=6/group	Slight irritation @ 2.5 & 5.0 ppm	Stepan Study No. 88-026A
Primary Skin Irritation Study (rabbit) (24 hr. contact time) n=9	PII=6.54/8.0 (severely irritating to skin @ greater than 5% active)	Stepan Study No. 04-002C
Skin Irritation Study (rat) (2 weeks) (repeated dermal applications)	No skin irritation was observed at concentrations less or equal to 1%.	Stepan Study No. 5036

© 2008, Stepan Company. All rights reserved.

Nothing contained herein grants or extends a license, expressed or implied, in connection with patents, issued or pending, of the manufacturer or others. The information contained herein is based on the manufacturer's own study and the work of others. The manufacturer makes no warranties, expressed or implied, as to the accuracy, completeness, or adequacy of the information contained herein. The manufacturer shall not be liable (regardless of fault) to the vendee's employees, or anyone for any direct, special or consequential damages arising out of or in connection with the accuracy, completeness adequacy or furnishing of such information.

Test/Conditions	Results/Classification	References
Photoallergy Study (modified Buehler test) (guinea pig)	There was no evidence of photoallergy or contact sensitization at 0.25%. @0.4 ml of 1% w/w mixture of test substance in distilled water	Stepan Study No. 05-019A
Subchronic Dermal Toxicity (rat)(90 Day)	No systemic toxicity observed at 20 mg/kg/day.	Stepan Study No. 90-012A
Repeated Oral Dose (mice)(dietary)(90 days)	NOEC = 500ppm	Stepan Study No. 88-040A
Chronic Oral Toxicity (dog)(diet)(1 year)	No effects for systemic toxicity observed at 400 ppm. No specific target organ toxicity observed. Treatment had no effect on survival.	Stepan Study No. 94-014A
Chronic/Oncogenicity Study (mouse)(diet)(78 week) n=60	No effects levels were determined to be at or less than 500 ppm. No specific target organ toxicity observed. Treatment did not have any affect on survival or tumor incidence.	Stepan Study No. 91-067A
Chronic/Oncogenicity Study (rat)(diet) (104 weeks) n=60	No-effect levels were determined to be at 1000 ppm. No specific target organ toxicity was observed. Treatment did not have any effect on survival or tumor incidence.	Stepan Study No. 91-066A
Developmental Toxicity (rat)(gavage) n=100	No effect levels at 10 mg/kg/day were determined for maternal toxicity. Treatment had no effects on fetal development.	Stepan Study No. 92-013A
Developmental Toxicity (rabbit)(gavage) n=64	No effect levels at 3 mg/kg/day were determined for maternal toxicity. Treatment had no effects on fetal development.	Stepan Study No. 92-014A

© 2008, Stepan Company. All rights reserved.

Nothing contained herein grants or extends a license, expressed or implied, in connection with patents, issued or pending, of the manufacturer or others. The information contained herein is based on the manufacturer's own study and the work of others. The manufacturer makes no warranties, expressed or implied, as to the accuracy, completeness, or adequacy of the information contained herein. The manufacturer shall not be liable (regardless of fault) to the vendee's employees, or anyone for any direct, special or consequential damages arising out of or in connection with the accuracy, completeness adequacy or furnishing of such information.

Test/Conditions	Results/Classification	References
Two-Generation Reproduction Study (rat)(diet) n=28/dose/sex	No effect levels for parental and neonatal toxicity were determined to be at or less than 1000 ppm. Treatment did not have an effect on any of the reproductive parameters.	Stepan Study No. 90-016A
Mutagenicity (Ames Test)	Not-mutagenic	Stepan Study No. 01-035A
CHO/HGPRT Forward Mutation Assay (Mutagenicity Test)	Not mutagenic	Stepan Study No. 89-025A
Primary Hepatocyte Unscheduled DNA Synthesis Assay (Mutagenicity Test)	Not mutagenic	Stepan Study No. 89-019A
Unscheduled DNA Synthesis- Independent Repeat (Genotoxicity Test) (rat liver cells)	Not mutagenic	Stepan Study No. 92-012A

Expert Panel Review of benzalkonium chloride, an alkyl dimethyl benzyl ammonium chloride quat: The Cosmetic Ingredient Review (CIR) Expert Panel concluded that benzalkonium chloride at concentrations up to 0.1% free, active ingredient, is safe as a cosmetic ingredient as presently used.

¹PII=Primary Skin Irritation Index

References:

*Journal of the American College of Toxicology (JACT), Vol. 8 (4), 1989, pp. 600-609.

BTC® ; SO/SAN® ; ® are registered trademarks of Stepan Company.

Last Update: 2.8.10 Revision Reference: TX017.04

Last Modified by: Barbara Gomez on 02/08/2010 01:49:57 PM

© 2008, Stepan Company. All rights reserved.

Nothing contained herein grants or extends a license, expressed or implied, in connection with patents, issued or pending, of the manufacturer or others. The information contained herein is based on the manufacturer's own study and the work of others. The manufacturer makes no warranties, expressed or implied, as to the accuracy, completeness, or adequacy of the information contained herein. The manufacturer shall not be liable (regardless of fault) to the vendee's employees, or anyone for any direct, special or consequential damages arising out of or in connection with the accuracy, completeness adequacy or furnishing of such information.